Regeneron Pharmaceuticals Inc v Kymab Ltd
A patent claiming a range of products is invalid for insufficiency unless the specification enables the skilled person to make substantially all the products in the range, so a patent for genetically modified mice was invalid.
Facts
Regeneron held patents for a method of producing genetically modified mice whose immune systems would produce antibodies with human variable regions, for use in developing antibody drugs, and for the mice themselves. At the priority date, the specification did not enable the skilled person to make such mice with more than a small part of the range of human variable region genes covered by the claims, because of a technical difficulty which was overcome only later. Regeneron sued Kymab, a competitor which had developed its own mice, for infringement, and Kymab argued that the patents were invalid for insufficiency.
Legal principle
The Supreme Court, by a majority, held that the patents were invalid. Lord Briggs said that, where a patent claims a range of products, the specification must enable the skilled person to make substantially all the types or embodiments of products within the claimed range, because the patentee's monopoly must be justified by the contribution to the art which the patent makes. Since the specification did not enable the skilled person to make mice across most of the range, the contribution did not justify a monopoly over the whole range, even though the invention was a significant advance. The court considered the approach of the European Patent Office. Lady Black dissented, holding that the invention's contribution was the use of a principle across all mice.
Related cases on patents: patentability and validity
- Aerotel Ltd v Telco Holdings Ltd; Macrossan's Application [2006] EWCA Civ 1371, [2007] RPC 7
- Biogen Inc v Medeva plc [1997] RPC 1
- Conor Medsystems Inc v Angiotech Pharmaceuticals Inc [2008] UKHL 49, [2008] RPC 28
- Emotional Perception AI Ltd v Comptroller General of Patents, Designs and Trade Marks [2026] UKSC 3
- Generics (UK) Ltd v H Lundbeck A/S [2009] UKHL 12, [2009] RPC 13
- Human Genome Sciences Inc v Eli Lilly & Co [2011] UKSC 51, [2012] RPC 6
- Merrell Dow Pharmaceuticals Inc v HN Norton & Co Ltd [1996] RPC 76
- Oliver Brüstle v Greenpeace eV Case C-34/10, [2011] ECR I-9821
Studying intellectual property law? Our tutors help you understand and apply cases like this in essays, problem questions and exams. Request a quote or browse our law notes.
This summary is for study and revision and is not legal advice. Although our case summaries are checked for accuracy, we do not guarantee that they are free from errors or omissions. Always read the full judgment for the court's reasoning.
